ASKG 812
Alternative Names: ASKG-812Latest Information Update: 19 Jun 2024
At a glance
- Originator AskGene Pharma
- Class Antibodies; Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action Interleukin 2 replacements; Programmed cell death 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 05 Apr 2024 Interim pharmacodynamics data from a preclinical studies in cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 22 Dec 2023 Preclinical trials in Cancer in USA (Parenteral) prior to December 2023 (AskGene Pharma pipeline, December 2023)
- 11 Jan 2021 AskGene files a PCT patent application with WIPO for ASKG 812 worldwide